Current classifications differ in the characterization of these patients, since NPM1 mutation constitutes an adequate criterion for AML diagnosis in WHO 2022 classification, while the ICC requires the 10% blast percentage as a co-criterion for the establishment of AML diagnosis, thus labeling as MDS patients with a lower blast- (or blast equivalent) cell percentage. This evidence concerns the gene NPM1 and myelodysplastic syndrome.